Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Kidney cancer in 2014: Key advances promise progress for kidney cancer patients.

Literature DB >> 25600094

Kidney cancer in 2014: Key advances promise progress for kidney cancer patients.

Timothy Ito¹, Alexander Kutikov¹.

Abstract

Entities: Disease Species

Mesh：

Substances：

Year: 2015 PMID： 25600094 DOI： 10.1038/nrurol.2014.356

Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432

× No keyword cloud information.

10 in total

1. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

Authors: Bernard Escudier; Camillo Porta; Petri Bono; Thomas Powles; Tim Eisen; Cora N Sternberg; Jürgen E Gschwend; Ugo De Giorgi; Omi Parikh; Robert Hawkins; Emmanuel Sevin; Sylvie Négrier; Sadya Khan; Jose Diaz; Suman Redhu; Faisal Mehmud; David Cella
Journal: J Clin Oncol Date: 2014-03-31 Impact factor: 44.544

2. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.

Authors: Hendrik Van Poppel; Luigi Da Pozzo; Walter Albrecht; Vsevolod Matveev; Aldo Bono; Andrzej Borkowski; Marc Colombel; Laurence Klotz; Eila Skinner; Thomas Keane; Sandrine Marreaud; Sandra Collette; Richard Sylvester
Journal: Eur Urol Date: 2010-12-22 Impact factor: 20.096

Review 3. Is radical nephrectomy a legitimate therapeutic option in patients with renal masses amenable to nephron-sparing surgery?

Authors: Jeffrey J Tomaszewski; Marc C Smaldone; Robert G Uzzo; Alexander Kutikov
Journal: BJU Int Date: 2014-08-13 Impact factor: 5.588

4. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.

Authors: Robert J Motzer; Thomas E Hutson; Lauren McCann; Keith Deen; Toni K Choueiri
Journal: N Engl J Med Date: 2014-05-01 Impact factor: 91.245

5. PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinoma.

Authors: Maxine Sun; Alessandro Larcher; Jonas Schiffmann; Pierre I Karakiewicz
Journal: J Clin Oncol Date: 2014-09-29 Impact factor: 44.544

6. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904.

Authors: Emil Scosyrev; Edward M Messing; Richard Sylvester; Steven Campbell; Hendrik Van Poppel
Journal: Eur Urol Date: 2013-07-02 Impact factor: 20.096

7. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245

1 in total

1. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.

Authors: Hai Huang; Yi Gao; Ao Liu; Xiaoqun Yang; Fang Huang; Le Xu; Xu Danfeng; Lu Chen
Journal: EBioMedicine Date: 2019-10-26 Impact factor: 8.143